Egypt reorganised its medicines and devices regulator in 2019, and the consequence for a foreign manufacturer is sharper than it first looks. For medicines you can replace a distributor on your own authority. For devices, in most cases, you cannot.
Law No. 151 of 2019 created the Egyptian Drug Authority, and Prime Minister Decree No. 777 of 2020 set out what it does. Article 13 is the one that matters: the Authority replaces the Ministry of Health and Population, and its Chairman replaces the Minister, across the registration and circulation powers that previously sat under Law No. 127 of 1955. It absorbed the national control laboratory and the biological products body at the same time. Nothing may be circulated in Egypt as a medical product or device without its prior approval.
It is worth being precise about how complete that transfer was, because a looser version circulates. In February 2026 the Supreme Constitutional Court struck down a 2023 decision of the Authority’s Chairman that had replaced the controlled-substance schedules, holding that he had encroached on the Health Minister’s own powers and that the Authority’s founding law gave him no basis for it. Scheduling returned to the Minister the same day. The Authority is the regulator for registration, licensing and inspection; it is not a wholesale successor to the Ministry in every respect.
Public buying runs on a separate track again. The same 2019 law created a unified procurement body with exclusive authority to buy medicines and medical equipment for government and public entities, charging the requesting entity a percentage of the value procured. It opened a single digital portal for suppliers and public health entities in December 2025. A distributor that sells well into private hospitals and pharmacies may have no standing at all in the public channel, and the two capabilities have to be assessed separately rather than assumed to travel together.
Whoever files in Egypt is local. The Authority’s guidelines describe the applicant for registration as an importing company, a local facility or a scientific office, each with an Egyptian commercial register entry. The foreign licence holder supplies authenticated declarations from the country of origin, but the file in Cairo stands in a local name. That is the arrangement a brand should assume it is entering, and the question that decides how much it costs is not how registration begins. It is what happens when it ends.
For medicines, the answer is favourable and not widely understood. Changing the registration applicant for an imported product is handled as the lightest class of variation, with no additional technical requirements, and the evidence of the outgoing party can take either of two forms: a termination letter issued by the licence holder, authenticated and translated, or a waiver from the departing applicant attested by a bank. Either satisfies the file. A manufacturer that has terminated properly under its own agreement is therefore not dependent on the goodwill of the company it has just terminated.
For devices, the answer runs the other way. Under the guideline that took effect on 1 September 2025, transferring an existing device licence to a new applicant requires a waiver from the old applicant signed off at board level and attested, alongside a termination letter from the legal manufacturer. The route that moves an appointment from an agent to a scientific office requires the same waiver. Only a transfer to an affiliated scientific office avoids it. If the waiver is not produced, the new applicant has to submit a fresh registration, and is then allowed one year to keep importing while that application runs, because the device is already on the Egyptian market.
That one-year grace period is the measure of the risk, and it is also the reason the clause matters at contract stage rather than at exit. A device company that has not agreed in writing, in advance, that its Egyptian partner will sign a waiver on termination is relying on a signature it cannot compel from a counterparty with every reason to withhold it.
The population of credible counterparties is defined by licensing rather than by size. Storage and distribution of pharmaceutical and biological products, medical devices, cosmetics, raw materials and disinfectants all fall under the same good storage and distribution regime, administered and inspected by the Authority’s central inspection administration, which issues the certificates and can suspend an operation on the strength of a technical memorandum.
Two features of that regime narrow the field in ways a desk search will not show. Suppliers must be licensed to distribute, and customers must themselves hold an activity licence from the Authority, with a file kept containing the customer’s store licence. The licensing status of a distributor’s own customer base is therefore part of what you are buying, and a partner whose downstream accounts are informal is a partner whose route to market can be closed without anyone touching your product.
Nationally licensed wholesalers. Companies holding the full storage and distribution certificate, inspected on the warehouse rather than on the company profile. This is the group that can legitimately hold registered medicines and devices, and the group worth starting from.
Scientific offices. A licensed form that can act as the registration applicant and carry promotional and regulatory responsibility without taking title. Useful where a manufacturer wants the file held by an entity under its own influence rather than by a trading counterparty.
Device specialists. Often narrower operations built around tender work, service engineers and installed base rather than around warehouse throughput. Capability here is judged on the service organisation, not on storage volume.
Public channel suppliers. Companies with standing in the unified procurement process. Worth identifying separately, because performance in private pharmacy and hospital sales predicts very little about it.
These are the things to see evidence of, rather than ask about. Each is documentary, each is current as of November 2026, and each is a point where a company that describes itself as a distributor may turn out to be something else.
The first three are specific to Egypt and are the ones most often skipped. None of them can be answered from a company website, and most cannot be answered from a register either.
For devices especially, agree now that the partner will execute a board-level attested waiver on termination, and make it a condition rather than a courtesy. The alternative is re-registration with a one-year clock running.
An importing company, a local facility and a scientific office are three different answers with three different consequences for control. Decide which you want before a candidate decides for you.
Entry on the register is what lets a company import for trade at all. The general rule remains majority Egyptian ownership; a 2023 amendment opened a capped, temporary route for foreign-owned entities, and the executive regulation was replaced in July 2026. Ask which basis the candidate is registered on and when that entry expires.
Ask for named accounts in each. A company that sells to private hospitals and one that wins through the unified procurement process are doing different jobs with different people.
Medicine pricing is set by reference to the lowest price in designated reference countries, certificates run for five years, and re-pricing is triggered by currency movement or by a capped annual allowance. Work out what that does to your landed economics before you negotiate a margin.
Inspection is real, and the regulator can suspend an operation on the strength of one. A candidate unable to discuss any finding has not been examined closely, and that absence is itself worth knowing.
Batches of biological products go through lot release before reaching the market, with a faster path where a certificate from a recognised authority allows reliance. The route your product qualifies for changes the working capital the relationship needs.
The single most common failure in Egyptian healthcare distribution, and the most expensive. A relationship ends, the incumbent declines to sign, and the brand discovers that the licence it treated as its own is held in a name that will not release it.
A commercial agent and a distributor are different legal animals in Egypt. The agent has to be registered and wholly Egyptian-owned; a distributor taking title does not need that registration but does need to be on the importers register. Papering one as the other creates an arrangement that may not do what either party expected.
Coverage claims that rest on unlicensed downstream accounts evaporate under inspection, and they evaporate at the worst moment, which is after your stock is in the country.
Mapping studies, calibrated devices and reviewed transport data are all required, and all are things a company can describe without doing. The gap shows up as product that has technically been out of band and has not been reported.
It is partly a regulatory output. A margin agreed without reference to how the price is set, and to what triggers a re-pricing, is a margin agreed in the wrong currency of argument.
Egyptian law supplies a default position on exclusivity in agency arrangements that the parties can vary by agreement. Assuming the default, in either direction, is how two companies end up with different beliefs about the same contract.
The applicant named on the Egyptian file is a local entity: an importing company, a local facility or a scientific office. The foreign licence holder supplies the authenticated declarations behind it and retains contractual control through the authorisation and termination letters. The practical route to holding the file in an entity you control is a scientific office rather than a trading distributor.
For medicines, no, provided you can produce a termination letter from the licence holder; a waiver from the outgoing applicant is an alternative, not a requirement. For devices, a board-level attested waiver from the outgoing applicant is required on the main transfer routes, and without it the incoming partner has to register again, with a one-year window to keep importing meanwhile.
To be entered on the importers register and import for trade, the general rule is still majority Egyptian ownership with an Egyptian national responsible for importing. A 2023 amendment created a capped and time-limited route for foreign-owned companies, and the executive regulation was replaced in July 2026. Reports that the ownership requirement was simply removed are wrong.
Devices sit under the Drug Authority through its founding law and the 2020 decree, implemented through the Authority’s own guidelines rather than through a dedicated device statute. Registration runs through the central administration for medical devices, and a licence lasts ten years.
A unified procurement authority has exclusive responsibility for buying medicines and medical equipment for government and public entities, and operates a digital portal for suppliers. Private-sector distribution strength is not a proxy for standing there.
It depends on the route, and the Authority publishes working-day timelines for several of them: lot release for biological products runs from five working days where reliance on a recognised authority is available to roughly a month on the normal track. Registration and variation timelines vary by class and are better established product by product than quoted as a single figure.
Tell us the product class and whether you are entering Egypt or replacing an existing partner there. We will tell you what can be established from the regulatory record and what will take conversations with the companies themselves.
How we verify How a distributor search runs